Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have competed for decades. In recent years, these two healthcare leaders have also been butting heads in the GLP-1 weight loss space. Eli Lilly's ...
Weight-loss drugs like Ozempic can impact holiday eating. Doctors explain how to enjoy holiday foods without side effects and ...
On its own, obesity can cause acute ailments, including breathlessness and back pain. Worse, it often leads to other chronic ...
The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...
Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...
On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback